Can a new drug safely control eczema over the long haul?

NCT ID NCT07734415

ENROLLING_BY_INVITATION Disease control Sponsor: Inmagene LLC Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial is investigating whether long-term use of an experimental drug called IMG-007 can safely control moderate-to-severe eczema (atopic dermatitis). The study enrolls people who have already completed a previous IMG-007 trial and will receive the drug as a shot under the skin. Researchers are monitoring for side effects and checking how well the drug keeps eczema in check over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called IMG-007
What this could lead to: If it works, this could point toward a long-term treatment option for people with moderate-to-severe eczema.
What could go wrong: This is an early-stage extension study, so the drug's long-term safety and effectiveness are still unproven. Side effects may emerge with longer use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema immune system disorder skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS ATOPIC DERMATITIS ECZEMA ECZEMA

Contacts and locations

Locations

Inmagene Site 1

Lancaster, California, 93534, United States
Inmagene Site 10

Fargo, North Dakota, 58103, United States
Inmagene Site 11

Woodbury, New York, 11797, United States
Inmagene Site 12

Anderson, South Carolina, 29621, United States
Inmagene Site 13

Mississauga, Ontario, L4Y 4C5, Canada
Inmagene Site 14

Montreal, Quebec, H2X 2V1, Canada
Inmagene Site 15

Surrey, British Columbia, V3R 6A7, Canada
Inmagene Site 16

Saskatoon, Saskatchewan, S7K 2C1, Canada
Inmagene Site 17

Greater Sudbury, Ontario, P3C 1X8, Canada
Inmagene Site 18

North Bay, Ontario, P1B 3Z7, Canada
Inmagene Site 19

Ocala, Florida, 34470, United States
Inmagene Site 2

Rolling Meadows, Illinois, 60008, United States
Inmagene Site 20

Charlotte, North Carolina, 28277, United States
Inmagene Site 21

New York, New York, 10029, United States
Inmagene Site 22

Vancouver, British Columbia, V6H 4B1, Canada
Inmagene Site 23

Los Angeles, California, 90095, United States
Inmagene Site 3

Portland, Oregon, 97210, United States
Inmagene Site 4

Tampa, Florida, 33609, United States
Inmagene Site 5

Mayfield Heights, Ohio, 44124, United States
Inmagene Site 6

Kew Gardens, New York, 11415, United States
Inmagene Site 7

Burien, Washington, 698168, United States
Inmagene Site 8

Southlake, Texas, 76092, United States
Inmagene Site 9

Columbus, Ohio, 43213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.